Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Hutchison China MediTech Ltd (HCM US)
Watchlist
40
Analysis
Health Care
•
Hong Kong
Hutchison China MediTech Ltd develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. Hutchison China MediTech markets its products globally.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
Weibo Corp
•
22 Nov 2021 15:45
Weibo Secondary Listing - Needs to Come at a Discount
Weibo plans to raise around US$500-700m in its secondary listing in Hong Kong. In this note, we talk about the deal and its impact.
Sumeet Singh
Follow
279 Views
Share
bullish
•
Hutchmed China Ltd
•
22 Jun 2021 08:38
Pre-IPO Hutchmed China Ltd (13.HK) - The Strength and the Concerns
The article analyzed Hutchmed in terms of its business analysis, financial performance, pipeline, comparison with other biotech companies, and also...
Xinyao (Criss) Wang
Follow
262 Views
Share
bullish
•
Hutchmed China Ltd
•
19 Jun 2021 17:09
HutchMed Secondary Listing: HK-ADS Premium/(Discount) Views
HutchMed has launched a $603 million secondary listing on HKEx. In this note, we will look at HutchMed’s potential HK-ADS premium/(discount).
Arun George
Follow
312 Views
Share
bullish
•
Hutchmed China Ltd
•
18 Jun 2021 16:08
HCM Secondary Listing: Not a Good Performer
After its failed listing attempt 2019, today HCM launched its book building to raise USD 590m in its secondary listing in Hong Kong. We look at...
Ke Yan, CFA, FRM
Follow
403 Views
Share
bearish
•
Alibaba Group Holding
•
08 Jun 2021 14:24
China ADRs - A New Act Aims to Put an End to China ADR IPOs
On 27th May 2021, U.S. Senators Marco Rubio and Bob Casey introduced the No IPOs for Unaccountable Actors Act, which aims to prohibit IPO on U.S....
Sumeet Singh
Follow
305 Views
Share
First
Previous
1
2
3
4
5
6
7
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.34.5
x